GURUFOCUS.COM » STOCK LIST » Industrials » Construction » Nova Pharma Solutions Bhd (XKLS:03006) » Definitions » Risk Assessment

Nova Pharma Solutions Bhd (XKLS:03006) Risk Assessment


View and export this data going back to 2018. Start your Free Trial

What is Nova Pharma Solutions Bhd Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Nova Pharma Solutions Bhd is: No Data: Cannot be evaluated.


Competitive Comparison of Nova Pharma Solutions Bhd's Risk Assessment

For the Engineering & Construction subindustry, Nova Pharma Solutions Bhd's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nova Pharma Solutions Bhd's Risk Assessment Distribution in the Construction Industry

For the Construction industry and Industrials sector, Nova Pharma Solutions Bhd's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Nova Pharma Solutions Bhd's Risk Assessment falls into.



Nova Pharma Solutions Bhd  (XKLS:03006) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.


Nova Pharma Solutions Bhd Risk Assessment Related Terms

Thank you for viewing the detailed overview of Nova Pharma Solutions Bhd's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.


Nova Pharma Solutions Bhd Business Description

Traded in Other Exchanges
N/A
Address
Jalan USJ 25/1, Level 5, Suite C-5-1 & 2, Block C, Sky Park, One City, Subang Jaya, SGR, MYS, 47650
Nova Pharma Solutions Bhd provides engineering solutions to pharma and biotech industries. The company's reportable segments include Design fee, Post Design, & Other support fees. Design fee comprises conceptual designs which include user requirement specification, capacity analysis and process scheduling with detailed costing, list of deliverables, details specification of various equipment and processes. Post design fee comprise tendering and procurement support as well as the construction of a plant, & Other support fees comprise of services to assist a customer in the good manufacturing practice document review & gap analysis and assessment. It generates a majority of its revenue from the Design fee segment. Geographically, the company generates a majority of its revenue from Malaysia.

Nova Pharma Solutions Bhd Headlines

No Headlines